Table 2 FOXP3 expression prior and after the initiation of anti-IL1 therapy (A and B) in the index patient and FOXP3 expression in the mother (untreated). Notable increased expression of FOXP3 can be observed after anti-IL1 therapy was initiated
From: Immunological repertoire linked to PSTPIP1-associated myeloid-related inflammatory (PAMI) syndrome
Immunological Profile | Index Patient – A (%) | Index Patient – B (%) | Mother (%) | IPEX Patient (%) |
|---|---|---|---|---|
CD4+CD25+CD127-FOXP3 | 12,4 | 58,2 | 77,9 | 9,18 |
CD4+CD28null | 37,6 | 0,92 | 1,25 | 1,58 |
CD4+CD28null FOXP3+ | 21,5 | 33,2 | 19,4 | 0,00 |
CD4+FOXP3+ | 63,5 | 14,7 | 14,4 | 0,00 |
CD4+CD25+FOXP3+ | 33,5 | 51,4 | 47,5 | 0,74 |
CD8+FOXP3+ | 8,44 | 11,5 | 9,3 | 0,00 |
CD8+CD28null | 87,9 | 16,7 | 10,7 | 16,20 |
CD8+CD28null FOXP3+ | 7,39 | 14,9 | 7,32 | 1,39 |